Sandra Bohn Thomsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sandra Bohn Thomsen has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Kristine Højgaard Allin
Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
3 shared publications - Rahma Elmahdi
PREDICT Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
2 shared publications - Tine Jess
Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
2 shared publications - Anders Neumann
Department of Internal Medicine, Viborg Regional Hospital, Viborg, Denmark
1 shared publication Anette Mertz Nielsen
The Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
1 shared publication- Anette Mertz Nielsen
Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 5 March 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 45, 101332
Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial
- 5 March 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 45, 101332
Open AccessLow-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial
- Open Access
- 1 March 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (3) , e220595
Development of Cancer Among Patients With Pediatric-Onset Inflammatory Bowel Disease
The hallmarks of inflammatory bowel disease (IBD), a chronic immune-mediated inflammatory disease of the gastrointestinal tract, are progressive intestinal injury and systemic inflammation, which can lead to complications such as cancer. Inflammatory bowel disease is associated with an increased risk of several types of cancer, including colon, small bowel, and upper gastrointestinal tract cancers.1 In contrast to the risk of cancer among adult patients with IBD, the risk of cancer among patients with pediatric-onset IBD is not well investigated, to our knowledge. Pediatric patients with IBD may have longer durations of exposure to the chronic inflammatory state and thereby a higher risk of cancer.2 Furthermore, among children, the incidence of IBD and the risk of cancer have increased in recent years.3,4
- 1 March 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (3) , e220595
Open AccessDevelopment of Cancer Among Patients With Pediatric-Onset Inflammatory Bowel Disease
The hallmarks of inflammatory bowel disease (IBD), a chronic immune-mediated inflammatory disease of the gastrointestinal tract, are progressive intestinal injury and systemic inflammation, which can lead to complications such as cancer. Inflammatory bowel disease is associated with an increased risk of several types of cancer, including colon, small bowel, and upper gastrointestinal tract cancers.1 In contrast to the risk of cancer among adult patients with IBD, the risk of cancer among patients with pediatric-onset IBD is not well investigated, to our knowledge. Pediatric patients with IBD may have longer durations of exposure to the chronic inflammatory state and thereby a higher risk of cancer.2 Furthermore, among children, the incidence of IBD and the risk of cancer have increased in recent years.3,4
- 25 January 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (9) , 1128-1138
Impact of thiopurine discontinuation at anti‐tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study
Summary: Background: Escalation to anti‐tumour necrosis factor (anti‐TNF) in inflammatory bowel disease (IBD) patients on thiopurine is a common clinical scenario. However, the impact of discontinuing thiopurine at escalation is unclear.Aim: To assess the impact of discontinuing versus continuing thiopurine therapy at anti‐TNF initiation.Methods: We used the Danish registries to establish a national cohort of patients with IBD on thiopurine therapy prior to initiating anti‐TNF from 2003 to 2018. We compared patients discontinuing thiopurine therapy within 90 days of anti‐TNF initiation to those continuing. Our primary outcome was a composite of any new oral corticosteroid use, IBD‐related hospitalization, surgery or death. We used Cox regression models to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).Results: Of the 10,352 anti‐TNF exposed patients, 2,630 (1590 Crohn's disease (CD) and 1040 ulcerative colitis (UC)) received thiopurines prior to anti‐TNF. After anti‐TNF initiation, 979 patients discontinued thiopurines. Discontinuing thiopurines within 90 days of anti‐TNF initiation, increased the risk of the primary outcome (aHR: 1.22; 95% CI: 1.10‐1.36), particularly for IBD‐related hospitalization (aHR: 1.14; 95% CI: 1.00‐1.31) and oral corticosteroid use (aHR: 1.27; 95% CI: 1.13‐1.44). This increased risk of the primary outcome was seen in both CD (aHR: 1.17; 95% CI 1.02‐1.34) and UC (aHR: 1.32; 95% CI: 1.12‐1.55).Conclusions: In a nationwide cohort study of IBD patients, we observed that discontinuing thiopurines after anti‐TNF initiation was associated with an increased risk of adverse outcomes, in particular an increase in hospitalizations. Further interventional studies exploring this common clinical scenario are required.
- 25 January 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (9) , 1128-1138
Impact of thiopurine discontinuation at anti‐tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study
Summary: Background: Escalation to anti‐tumour necrosis factor (anti‐TNF) in inflammatory bowel disease (IBD) patients on thiopurine is a common clinical scenario. However, the impact of discontinuing thiopurine at escalation is unclear.Aim: To assess the impact of discontinuing versus continuing thiopurine therapy at anti‐TNF initiation.Methods: We used the Danish registries to establish a national cohort of patients with IBD on thiopurine therapy prior to initiating anti‐TNF from 2003 to 2018. We compared patients discontinuing thiopurine therapy within 90 days of anti‐TNF initiation to those continuing. Our primary outcome was a composite of any new oral corticosteroid use, IBD‐related hospitalization, surgery or death. We used Cox regression models to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).Results: Of the 10,352 anti‐TNF exposed patients, 2,630 (1590 Crohn's disease (CD) and 1040 ulcerative colitis (UC)) received thiopurines prior to anti‐TNF. After anti‐TNF initiation, 979 patients discontinued thiopurines. Discontinuing thiopurines within 90 days of anti‐TNF initiation, increased the risk of the primary outcome (aHR: 1.22; 95% CI: 1.10‐1.36), particularly for IBD‐related hospitalization (aHR: 1.14; 95% CI: 1.00‐1.31) and oral corticosteroid use (aHR: 1.27; 95% CI: 1.13‐1.44). This increased risk of the primary outcome was seen in both CD (aHR: 1.17; 95% CI 1.02‐1.34) and UC (aHR: 1.32; 95% CI: 1.12‐1.55).Conclusions: In a nationwide cohort study of IBD patients, we observed that discontinuing thiopurines after anti‐TNF initiation was associated with an increased risk of adverse outcomes, in particular an increase in hospitalizations. Further interventional studies exploring this common clinical scenario are required.
- Open Access
- 1 February 2020
- Published by Wiley in United European Gastroenterology Journal
- Vol. 8 (1) , 68-76
Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study
Background: Thiopurine and allopurinol in combination are associated with clinical remission in inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared outcomes during exposure to both thiopurines and allopurinol versus thiopurines alone.Methods: We established a nationwide cohort of patients with inflammatory bowel diseases exposed to thiopurines ± allopurinol during 1999–2014, using registry data. Patients were followed until hospitalization, surgery, anti‐TNFα, or death (as a primary composite outcome). We used Poisson regression analyses to calculate incidence rate ratios overall and stratified by calendar period (assuming the combined exposure was unintended before 2009).Results: A total of 10,367 patients with inflammatory bowel diseases (Crohn’s disease, n = 5484; ulcerative colitis, n = 4883) received thiopurines. Of these, 217 (2.1%) also received allopurinol. During 24,714 person years of follow‐up, we observed 40 outcomes among thiopurine‐allopurinol‐exposed patients, and 4745 outcomes among those who were thiopurine exposed; incidence rate ratio, 1.26 (95% confidence interval, 0.92–1.73). The incidence rate ratios decreased over time: 4.88 (95% confidence interval 2.53–9.45) for 1999–2003, 2.19 (95% confidence interval, 1.17–4.09) for 2004–2008 and 0.80 (95% confidence interval, 0.52–1.23) for 2009–2014.Conclusion: Our nationwide inflammatory bowel disease cohort study shows that concomitant thiopurine‐allopurinol is as safe to use as thiopurines alone, with a tendency towards a positive effect on clinical outcomes in recent calendar periods when combined use was intended.
- 1 February 2020
- Published by Wiley in United European Gastroenterology Journal
- Vol. 8 (1) , 68-76
Open AccessOutcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study
Background: Thiopurine and allopurinol in combination are associated with clinical remission in inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared outcomes during exposure to both thiopurines and allopurinol versus thiopurines alone.Methods: We established a nationwide cohort of patients with inflammatory bowel diseases exposed to thiopurines ± allopurinol during 1999–2014, using registry data. Patients were followed until hospitalization, surgery, anti‐TNFα, or death (as a primary composite outcome). We used Poisson regression analyses to calculate incidence rate ratios overall and stratified by calendar period (assuming the combined exposure was unintended before 2009).Results: A total of 10,367 patients with inflammatory bowel diseases (Crohn’s disease, n = 5484; ulcerative colitis, n = 4883) received thiopurines. Of these, 217 (2.1%) also received allopurinol. During 24,714 person years of follow‐up, we observed 40 outcomes among thiopurine‐allopurinol‐exposed patients, and 4745 outcomes among those who were thiopurine exposed; incidence rate ratio, 1.26 (95% confidence interval, 0.92–1.73). The incidence rate ratios decreased over time: 4.88 (95% confidence interval 2.53–9.45) for 1999–2003, 2.19 (95% confidence interval, 1.17–4.09) for 2004–2008 and 0.80 (95% confidence interval, 0.52–1.23) for 2009–2014.Conclusion: Our nationwide inflammatory bowel disease cohort study shows that concomitant thiopurine‐allopurinol is as safe to use as thiopurines alone, with a tendency towards a positive effect on clinical outcomes in recent calendar periods when combined use was intended.
- 3 February 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (5) , 532-537
Validation of the ‘United Registries for Clinical Assessment and Research’ [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease
The ‘United Registries for Clinical Assessment and Research’ [UR-CARE] database is an initiative of the European Crohn’s and Colitis Organisation [ECCO] to facilitate daily patient care and research studies in inflammatory bowel disease [IBD]. Herein, we sought to validate the database by using fictional case histories of patients with IBD that were to be entered by observers of varying experience in IBD. Nineteen observers entered five patient case histories into the database. After 6 weeks, all observers entered the same case histories again. For each case history, 20 key variables were selected to calculate the accuracy for each observer. We assumed that the database was such that ≥ 90% of the entered data would be correct. The overall proportion of correctly entered data was calculated using a beta-binomial regression model to account for inter-observer variation and compared to the expected level of validity. Re-test reliability was assessed using McNemar’s test. For all case histories, the overall proportion of correctly entered items and their confidence intervals included the target of 90% (Case 1: 92% [88–94%]; Case 2: 87% [83–91%]; Case 3: 93% [90–95%]; Case 4: 97% [94–99%]; Case 5: 91% [87–93%]). These numbers did not differ significantly from those found 6 weeks later [NcNemar’s test p > 0.05]. The UR-CARE database appears to be feasible, valid and reliable as a tool and easy to use regardless of prior user experience and level of clinical IBD experience. UR-CARE has the potential to enhance future European collaborations regarding clinical research in IBD.
- 3 February 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (5) , 532-537
Validation of the ‘United Registries for Clinical Assessment and Research’ [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease
The ‘United Registries for Clinical Assessment and Research’ [UR-CARE] database is an initiative of the European Crohn’s and Colitis Organisation [ECCO] to facilitate daily patient care and research studies in inflammatory bowel disease [IBD]. Herein, we sought to validate the database by using fictional case histories of patients with IBD that were to be entered by observers of varying experience in IBD. Nineteen observers entered five patient case histories into the database. After 6 weeks, all observers entered the same case histories again. For each case history, 20 key variables were selected to calculate the accuracy for each observer. We assumed that the database was such that ≥ 90% of the entered data would be correct. The overall proportion of correctly entered data was calculated using a beta-binomial regression model to account for inter-observer variation and compared to the expected level of validity. Re-test reliability was assessed using McNemar’s test. For all case histories, the overall proportion of correctly entered items and their confidence intervals included the target of 90% (Case 1: 92% [88–94%]; Case 2: 87% [83–91%]; Case 3: 93% [90–95%]; Case 4: 97% [94–99%]; Case 5: 91% [87–93%]). These numbers did not differ significantly from those found 6 weeks later [NcNemar’s test p > 0.05]. The UR-CARE database appears to be feasible, valid and reliable as a tool and easy to use regardless of prior user experience and level of clinical IBD experience. UR-CARE has the potential to enhance future European collaborations regarding clinical research in IBD.